Merck To Incorporate Idera’s TLR Agonists Into Vaccine Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will pay Idera $20 million up front as part of deal.
You may also be interested in...
Merck KGaA Joins Rush To Develop Toll-Like Receptor 9 Agonists
Company signed a deal with Idera valued at $421 million, gaining two of its lead TLR9 candidates for oncology indications, excluding vaccines.
Merck KGaA Joins Rush To Develop Toll-Like Receptor 9 Agonists
Company signed a deal with Idera valued at $421 million, gaining two of its lead TLR9 candidates for oncology indications, excluding vaccines.
Pfizer Halts Lung Cancer Trials Of Toll-Like Receptor Agent
Fate of other oncology trials of the TLR9 candidate Pfizer licensed from Coley has not been made public.